1. Home
  2. RYTM vs PTEN Comparison

RYTM vs PTEN Comparison

Compare RYTM & PTEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • PTEN
  • Stock Information
  • Founded
  • RYTM 2008
  • PTEN 1978
  • Country
  • RYTM United States
  • PTEN United States
  • Employees
  • RYTM N/A
  • PTEN N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • PTEN Oil & Gas Production
  • Sector
  • RYTM Health Care
  • PTEN Energy
  • Exchange
  • RYTM Nasdaq
  • PTEN Nasdaq
  • Market Cap
  • RYTM 4.3B
  • PTEN 2.3B
  • IPO Year
  • RYTM 2017
  • PTEN 1993
  • Fundamental
  • Price
  • RYTM $65.77
  • PTEN $6.31
  • Analyst Decision
  • RYTM Strong Buy
  • PTEN Buy
  • Analyst Count
  • RYTM 12
  • PTEN 13
  • Target Price
  • RYTM $77.50
  • PTEN $9.85
  • AVG Volume (30 Days)
  • RYTM 631.5K
  • PTEN 12.6M
  • Earning Date
  • RYTM 08-05-2025
  • PTEN 07-23-2025
  • Dividend Yield
  • RYTM N/A
  • PTEN 5.07%
  • EPS Growth
  • RYTM N/A
  • PTEN N/A
  • EPS
  • RYTM N/A
  • PTEN N/A
  • Revenue
  • RYTM $136,863,000.00
  • PTEN $5,148,088,000.00
  • Revenue This Year
  • RYTM $37.56
  • PTEN N/A
  • Revenue Next Year
  • RYTM $74.99
  • PTEN N/A
  • P/E Ratio
  • RYTM N/A
  • PTEN N/A
  • Revenue Growth
  • RYTM 48.88
  • PTEN 5.82
  • 52 Week Low
  • RYTM $40.46
  • PTEN $5.12
  • 52 Week High
  • RYTM $69.89
  • PTEN $11.27
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 57.57
  • PTEN 56.51
  • Support Level
  • RYTM $60.80
  • PTEN $5.78
  • Resistance Level
  • RYTM $67.75
  • PTEN $6.06
  • Average True Range (ATR)
  • RYTM 2.08
  • PTEN 0.28
  • MACD
  • RYTM 0.26
  • PTEN 0.01
  • Stochastic Oscillator
  • RYTM 71.91
  • PTEN 60.95

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About PTEN Patterson-UTI Energy Inc.

Patterson-UTI Energy Inc is one of the substantial land rig drilling contractors in the United States. Its 2023 merger with NexTier greatly expanded its pressure pumping operations, as well, and the firm now controls nearly 20% of the North American market for drilling and completions services. The company operates under three reportable business segments: (i) drilling services, (ii) completion services, and (iii) drilling products. It also provides directional drilling services and tool rental services in united states onshore oil and gas basins.

Share on Social Networks: